Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer
Last Updated: Friday, March 5, 2021
This article summarizes the initial results from the trials of neoadjuvant immune checkpoint inhibitors in patients with early-stage and locally advanced operable NSCLC and review the findings of studies investigating emerging biomarkers associated with those trials.
Advertisement
News & Literature Highlights